PREVALENCE AND COST OF SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL POTENT CORTICOSTEROIDS
Author(s)
Cortesi PA1, Scalone L1, De Pità O2, Angelini G3, Cristaudo A4, Girolomoni G5, Gola M6, Ayala F7, Cannavò SP8, Satta R9, Gallo R10, Lisi P11, Peserico A12, Pigatto P13, Mantovani LG14, Belisari A15, Giannetti A161University of Milano - Bicocca, Monza, Ita
OBJECTIVES: Earlier research has shown that Hand Eczema (HE) is often work-related, widespread, potentially disabling and costly, but often misdiagnosed and mistreated. Severe Chronic Hand Eczema (CHE) can be particularly burdensome, especially among severe patients refractory to therapy. We assessed cost-of-illness of severe CHE patients refractory to topical potent corticosteroids and their prevalence among HE patients accessing dermatology centres. METHODS: a naturalistic, multicentre study was conducted in 14 Italian dermatology centers. HE patients aged ≥18 years, consecutively accessing the participating centers through a 6-month period were enrolled. Socio-demographic and clinical data were collected for all patients, while direct, indirect costs and HRQol data were collected on severe refractory CHE patients. HRQoL was collected with the EQ-5D and the condition-specific Dermatology-Life-Quality-Index (DLQI, having a summary score ranging from 0 to 30, higher score corresponds to more impaired HRQoL). Direct and indirect costs data were collected through a retrospective 8-week time horizon, using the societal perspective. RESULTS: in total 981 HE patients were enrolled (mean age+SD=39.1+15.1, 35.9% male), 11.0% had severe refractory CHE. DLQI mean+SD sum score was 11.3+6.3. With EQ-5D 96.2% of patients reported moderate or severe pain/discomfort, 73.1% problems with usual activities, 55.8% anxiety/depression and 52.9% problems with self-care. VAS mean+SD=60.4+23.3. On average hospitalizations cost 67.3€/patient-month, travels cost 43.4€/patient-month, specialist visits cost 41.0€/patient-month, other products (gloves, gauze bandage, vacuum cleaner, cosmetics) cost 27.2€/patient-month, diagnostic exams cost 19.6€/patient-month, non pharmacological therapy (emollients, galenic products, soap, UV-therapy) cost 18.7€/patient-month, pharmacological therapy cost 18.2€/patient-month. Patients lost on average 4.9 workdays/patient-month for reasons attributable to their disease. CONCLUSIONS: Approximately one tenth of HE patients accessing dermatology centers have severe refractory CHE. These generate high costs to manage their condition, and have a significant productivity loss and a poor HRQoL. An appropriate diagnosis and treatment is necessary to efficiently manage the disease.
Conference/Value in Health Info
2011-11, ISPOR Europe 2011, Madrid, Spain
Value in Health, Vol. 14, No. 7 (November 2011)
Code
PRS17
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders, Sensory System Disorders, Systemic Disorders/Conditions